Can You Take Saxenda with HRT? Safety Guide
Many women approaching or experiencing menopause consider weight management options such as Saxenda (liraglutide) alongside hormone replacement therapy (HRT). There is no contraindication to using GLP-1 medicines like Saxenda alongside HRT, and many patients safely receive both treatments. However, because GLP-1 medicines slow stomach emptying, they may affect how well your body absorbs some oral medicines, including oral forms of HRT. This matters most if you take oral progesterone as part of your HRT, because progesterone is what protects the lining of the womb. Do not stop or change your HRT unless advised to do so by your healthcare professional.
Summary: There is no contraindication to using Saxenda alongside HRT. However, because Saxenda slows stomach emptying, it may reduce how well your body absorbs oral progesterone, which is the part of HRT that protects the lining of the womb.
- There is no contraindication to using GLP-1 medicines such as Saxenda alongside HRT, and many patients safely receive both.
- Because Saxenda slows stomach emptying, it may affect the absorption of some oral medicines, including oral forms of HRT.
- This does not affect HRT given through the skin (patches, gels or sprays) or via an intrauterine system such as the Mirena coil.
- If you have a uterus and take oestrogen, progesterone protects the lining of the womb, so adequate endometrial protection must be maintained during GLP-1 treatment.
- The British Menopause Society recommends discussing either a switch to an LNG-IUD or a temporary progesterone dose increase for 4 weeks when starting treatment and after each dose increase.
- Contact your healthcare professional if you have unexpected vaginal bleeding after starting GLP-1 treatment.
Table of Contents
| Consideration | Saxenda (liraglutide) | HRT (oestrogen/progestogen) | Combined use |
|---|---|---|---|
| Mechanism of action | GLP-1 receptor agonist; reduces appetite, slows gastric emptying | Replaces declining oestrogen and progestogen during menopause | Different physiological systems; no direct pharmacological interaction |
| Gastrointestinal effects | Nausea, vomiting, diarrhoea, constipation; common during dose escalation | Oral preparations may cause GI symptoms in some women | Possible additive GI symptoms; transdermal HRT may reduce this risk |
| Absorption considerations | Slows gastric emptying; may theoretically affect oral drug absorption | Oral HRT absorption may be marginally affected; clinical impact unlikely | Transdermal HRT (patches, gels) unaffected by Saxenda; preferred if concern exists |
| Gallbladder risk | GLP-1 agonists increase gallstone risk; rapid weight loss adds further risk | Oral oestrogens may increase gallbladder disease risk | Combined use may increase gallbladder risk; monitor for right upper quadrant pain or jaundice |
| Cardiovascular considerations | May modestly increase heart rate; assess cardiovascular risk before use | Oral HRT carries higher VTE risk than transdermal; not indicated for CVD prevention | Full cardiovascular risk assessment required; transdermal HRT preferred in higher-risk women |
| Key monitoring | Weight, BMI, blood pressure, heart rate, blood glucose, mood | Blood pressure, cardiovascular risk factors, unusual bleeding, breast changes | Regular GP review recommended; report side effects via MHRA Yellow Card scheme |
| Contraindications and cautions | Not for use in pregnancy or breastfeeding; avoid with other GLP-1 agonists | Caution with history of VTE, breast cancer, or hormone-sensitive cancers | Disclose full medical history and all current medications to prescribing clinician before starting either treatment |
Can You Take Saxenda with HRT?
Yes. There is no contraindication to using GLP-1 medicines alongside HRT. Many patients safely receive both treatments.
However, because GLP-1 medicines slow stomach emptying, they may affect the absorption of some oral medicines, including oral forms of HRT. This does not affect HRT delivered through the skin (patches, gels or sprays) or via an intrauterine system (e.g. Mirena® coil).
Therefore, if you take oral progesterone (capsules) as part of your hormone replacement therapy (HRT), treatment with a GLP-1 weight loss medication such as Saxenda (liraglutide) may affect how well your body absorbs this medication, because these medicines delay stomach emptying. This may reduce the amount of progesterone available in your body.
Saxenda is a GLP-1 receptor agonist given as a daily subcutaneous injection for weight management, as an adjunct to a reduced-calorie diet and increased physical activity.[2][3] HRT replaces the hormones that decline during perimenopause and menopause. The two are prescribed for distinct clinical indications and each requires individual assessment.
Saxenda is contraindicated in pregnancy, and HRT is not a form of contraception. If you are of childbearing potential, you should use effective contraception while taking these medications.
Oral Progesterone and Endometrial Protection
If you have a uterus and are taking oestrogen as part of HRT, progesterone is important for protecting the lining of the womb (endometrium) from excessive thickening. For this reason, it is important to ensure your HRT continues to provide adequate endometrial protection while you are receiving GLP-1 treatment.
If you are taking oral progesterone, we recommend discussing your HRT with your prescribing healthcare professional. They can review your treatment and advise whether any changes are appropriate, such as adjusting your HRT regimen or considering a non-oral form of progesterone if clinically indicated.
If you take oral progesterone (such as Utrogestan or Provera), the British Menopause Society recommends speaking to your GP or menopause specialist or nurse about:
-
changing to a LNG-IUD (such as the Mirena® coil), or
-
temporarily increasing your progesterone tablet dose for 4 weeks when starting treatment, and for 4 weeks after each dose or strength increase.
This advice does not mean there will necessarily be a problem with your HRT. It is provided to ensure your treatment remains safe and effective while you are using GLP-1 weight loss medication. Do not stop or change your HRT unless advised to do so by your healthcare professional.
Please speak to your GP, nurse or menopause specialist before making any changes to your HRT.
How Saxenda and HRT Work in the Body
Saxenda (liraglutide) is a GLP-1 receptor agonist administered as a daily subcutaneous injection.[2][3] It mimics the action of naturally occurring GLP-1, a hormone released by the intestine in response to food intake. It works through several mechanisms:
-
Appetite regulation: it acts on areas of the brain involved in appetite control, helping to reduce hunger and increase feelings of fullness
-
Gastric emptying: it slows the rate at which food leaves the stomach, prolonging satiety after meals[4][5]
-
Glucose regulation: it improves insulin sensitivity and glucose metabolism
HRT supplements the declining levels of oestrogen, and where needed progesterone, that occur during perimenopause and menopause. Oral tablets are metabolised through the liver, whilst transdermal preparations such as patches, gels and sprays deliver hormones directly into the bloodstream, bypassing first-pass hepatic metabolism.
Because HRT acts on hormone receptors throughout the body whilst Saxenda acts on appetite regulation and glucose metabolism, the two do not compete for the same receptors or metabolic pathways. This is why there is no contraindication to using them together.
The consideration that does apply is absorption. The delayed gastric emptying that makes Saxenda work can also affect how well oral medicines are absorbed, and that includes oral forms of HRT. HRT delivered through the skin or via an intrauterine system does not pass through the stomach, so this consideration does not apply to those routes.
Will HRT Affect My Weight Loss?
Current evidence suggests:
-
HRT does not stop GLP-1 medicines working. In clinical practice, perimenopausal and postmenopausal women derive benefit from GLP-1 medication, and HRT has been shown in some studies to enhance the weight loss benefit from GLP-1 medication.
-
Treating menopause symptoms may help improve sleep, activity levels and overall wellbeing, which may indirectly support healthy weight management.
Weight management during menopause is a common concern, as hormonal changes can contribute to increased abdominal fat and metabolic changes. Some women report weight gain when starting HRT, though evidence suggests HRT does not directly cause weight gain and may help prevent the unfavourable redistribution of body fat associated with menopause.
When Should I Seek Medical Advice?
Contact your healthcare professional if you experience:
-
unexpected vaginal bleeding after starting GLP-1 treatment
-
worsening menopausal symptoms
-
persistent vomiting or diarrhoea, as this may reduce absorption of oral medicines, including oral HRT
-
inability to take oral medicines
-
severe abdominal pain
-
symptoms suggesting dehydration
-
concerns about your HRT or GLP-1 treatment
Seek urgent medical care if you have severe upper abdominal pain, with or without vomiting, fever or jaundice, as GLP-1 medicines are associated with gallbladder disease and, rarely, pancreatitis.
If you have diabetes and take insulin or a sulfonylurea, your medication may need adjustment to prevent hypoglycaemia. Report any suspected side effects via the MHRA Yellow Card scheme.
What to Discuss with Your GP Before Starting Treatment
Before starting Saxenda, HRT, or both together, a discussion with your GP or prescribing clinician is essential.
Prepare for your appointment by noting your current HRT formulation (type, dose and route of administration), how long you have been taking it, and how well it is controlling your symptoms. If you take oral progesterone, say so explicitly, as this is the part of your HRT most affected by delayed stomach emptying.
Medical history to share includes:
-
history of pancreatitis or gallbladder disease
-
cardiovascular disease or risk factors
-
personal or family history of breast cancer or other hormone-sensitive cancers
-
history of venous thromboembolism (blood clots)
-
kidney or liver problems
-
diabetes or other endocrine disorders
-
mental health conditions, including depression
-
pregnancy plans, current pregnancy, or breastfeeding status
-
thyroid conditions
Key topics to discuss include:
-
whether your HRT continues to provide adequate endometrial protection during Saxenda treatment
-
whether a non-oral form of progesterone, such as an LNG-IUD, would be appropriate
-
whether a temporary progesterone dose increase is needed when starting treatment or increasing your dose
-
monitoring requirements, including weight, blood pressure, heart rate and blood glucose
-
contraception if you are of childbearing potential
-
what to do if you experience unexpected vaginal bleeding
Regular follow-up allows monitoring of treatment effectiveness, side effects, and any necessary adjustments to either your HRT or your weight loss medication.
Scientific References
- Saxenda – European Medicines Agency EPAR.
- Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics.
- Liraglutide | Drugs – BNF – NICE.
- Liraglutide Biocon 6 mg/ml solution for injection in pre-filled pen – SmPC.
- Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
- Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.
- Victoza – European Medicines Agency EPAR.
- Menopause: identification and management (NG23) – Recommendations.
- Long-term benefits and risks of hormone replacement therapy – NICE consultation.
- Menopause: identification and management (NG23).
- Hormone-replacement therapy: updated advice.
- A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.
- Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
- Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.
- Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis.
- GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
- Psychiatric adverse events associated with semaglutide, liraglutide and other GLP-1 receptor agonists.
- MHRA finds evidence does not support a link between GLP-1 receptor agonists and suicidal and self-injurious thoughts and acts.
- Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.
- Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
- Liraglutide: a medicine to treat type 2 diabetes or obesity – NHS.
- Hurtado MD, Tama E, Fansa S, et al. (2024) Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause 31(4):266-274.
- Bechenati D, Castaneda R, de Jesus Rivera Gutierrez R, et al. (2025) One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women with and without Hormone Therapy. Journal of the Endocrine Society 9(Suppl 1):bvaf149.122.
- Castaneda R, Bechenati D, Tama E, et al. (2026) The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology & Women's Health 2(2):e118-e128.
- British Menopause Society - Consensus Statements and Tools for Clinicians.
Frequently Asked Questions
Does Saxenda interact with HRT?
There is no contraindication to using Saxenda alongside HRT, and many patients safely receive both treatments. However, because Saxenda slows stomach emptying, it may affect how well your body absorbs oral medicines, including oral forms of HRT. This does not affect HRT delivered through the skin or via an intrauterine system.
Does Saxenda affect oral progesterone?
It may reduce how well your body absorbs oral progesterone, which may lower the amount available in your body. If you have a uterus and take oestrogen as part of HRT, progesterone protects the lining of the womb, so it is important that your HRT continues to provide adequate endometrial protection. Speak to your prescribing healthcare professional before changing anything.
Should I switch to patches or a coil while taking Saxenda?
That is a decision for your GP or menopause specialist. HRT delivered through the skin (patches, gels or sprays) or via an intrauterine system such as the Mirena coil does not pass through the stomach, so delayed gastric emptying does not affect it. The British Menopause Society recommends discussing either a switch to an LNG-IUD or a temporary increase in your progesterone tablet dose for 4 weeks when starting treatment and after each dose increase.
When should I seek medical advice if I take HRT and Saxenda?
Contact your healthcare professional if you experience unexpected vaginal bleeding after starting treatment, worsening menopausal symptoms, persistent vomiting or diarrhoea, inability to take oral medicines, severe abdominal pain, or symptoms suggesting dehydration.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
